Related Experiment Video
Updated: Mar 17, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction
Jeng-Feng Lin1, Shun-Yi Hsu1, Ming-Sheng Teng2
1Division of Cardiology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City; ; School of Medicine, Tzu Chi University, Hualien;
Insights
Elevated activin A levels in ST-elevation myocardial infarction (STEMI) patients predict poorer left ventricular remodeling and increased risk of all-cause death. This biomarker indicates worse outcomes post-STEMI.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Research
Background:
- Activin A levels rise in various heart conditions, including ST-elevation myocardial infarction (STEMI).
- The prognostic value of activin A in STEMI patients requires further investigation.
Purpose of the Study:
- To determine if activin A levels can predict left ventricular remodeling, heart failure, and mortality in STEMI patients.
- To assess the association between activin A levels and clinical outcomes following STEMI.
Main Methods:
- 278 STEMI patients had activin A levels measured on day 2 of hospitalization.
- Echocardiography was performed at baseline and 6 months post-STEMI.
- Clinical events, including all-cause death and heart failure readmission, were followed for up to 3 years.
Main Results:
- Higher activin A levels correlated with lower LVEF and higher LVEDVI at 6 months.
- Activin A levels > 129 pg/ml predicted all-cause death (p=0.022) but not heart failure.
- Higher activin A was associated with higher triglycerides and lower LVEF during hospitalization.
Conclusions:
- Activin A levels exceeding 129 pg/ml are predictive of adverse left ventricular remodeling in STEMI patients.
- Elevated activin A levels serve as a significant predictor of all-cause mortality following STEMI.
Background:
Activin A levels increase in a variety of heart diseases including ST-elevation myocardial infarction (STEMI). The aim of this study is to investigate whether the level of activin A can be beneficial in predicting left ventricular remodeling, heart failure, and death in patients with ST-elevation myocardial infarction (STEMI).
Methods:
We enrolled 278 patients with STEMI who had their activin A levels measured on day 2 of hospitalization. Echocardiographic studies were performed at baseline and were repeated 6 months later. Thereafter, the clinical events of these patients were followed for a maximum of 3 years, including all-cause death and readmission for heart failure.
Results:
During hospitalization, higher activin A level was associated with higher triglyceride level, lower left ventricular ejection fraction (LVEF), and lower left ventricular end diastolic ventricular volume index (LVEDVI) in multivariable linear regression model. During follow-up, patients with activin A levels > 129 pg/ml had significantly lower LVEF, and higher LVEDVI at 6 months. Kaplan-Meier survival curves showed that activin A level > 129 pg/ml was a predictor of all-cause death (p = 0.022), but not a predictor of heart failure (p = 0.767).
Conclusions:
Activin A level > 129 pg/ml predicts worse left ventricular remodeling and all-cause death in STEMI.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests